ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - fosaprepitant as fosaprepitant dimeglumine 150 mg - powder for solution for infusion - aprepitant - emend iv 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

bayer israel ltd - acarbose 50 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.

ישראל - עברית - Ministry of Health

bayer israel ltd - acarbose 100 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - acarbose - טבליה - acarbose 50 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - acarbose - טבליה - acarbose 100 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה לאינפוזיה - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.